Burnishing its rare disease drug ambitions, Sanofi picks up fast FDA OK for Cablivi — courtesy of a $4.8B buyout
Following up on last fall’s European approval for caplacizumab as a new treatment for a rare blood disease, Sanofi today followed up with the key to the big market in the US. The FDA has come through with an OK based on Phase III and Phase II data for acquired thrombotic thrombocytopenic purpura (aTTP).
The drug will now hit the market as Cablivi — at a cost of $270,000 per course — after getting a priority review at the agency, which is quick at whisking through new drugs when none are approved for a condition like this.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.